This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric participants with treatment-resistant seizure disorders, including Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS). All participants have rolled over from previous trials: INS011-14-029 (NCT02324673) and INS011-15-054 (NCT02551731).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants With Adverse Events
Timeframe: Up to Week 50
Percentage of Participants With Serious Adverse Events
Timeframe: Up to Week 50
Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Values
Timeframe: Up to Week 50
Percentage of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings
Timeframe: Up to Week 48
Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs
Timeframe: Up to Week 50
Change From Baseline in Trough Plasma Levels of Cannabidiol and Its 7-OH Metabolite
Timeframe: Up to Week 50